BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will present several posters at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 annual meeting taking place November 10-14, 2018 at the International Convention Centre in Barcelona, Spain. Presentations highlight recent and emerging trends in the life sciences industry in areas including the risks and benefits of low pricing strategies, the impact of clinical trial design on market adoption, and access strategies and considerations for curative cell and gene therapies.
“The life sciences specialists at CRA are continually monitoring and analyzing the most recent data and trends affecting the sector as part of our commitment to helping our clients address the issues that affect their operations both regionally and globally,” said CRA Vice President, Joanne Clark. “Both the breadth and depth of our presentations at ISPOR Europe this year are a reflection of our ability to offer an insider’s perspective on issues related to pricing, access, drug development and commercialization, and many other areas.”
Leaders from the CRA Life Sciences Practice will present the following posters in the Exhibit Poster Hall during the ISPOR Europe meeting:
Monday, November 12, 2018
-
Title: Impact of Outcome Based Annuities on Small Biotech Companies
Authors: Joseph Nevins with Walter Colasante and Luka Jelcic
Research Poster Presentations: Session I
PCP: Conceptual Papers
Display Hours: 8:45 am to 1:45 pm CEST
-
Title: The Quantity and Quality of Evidence Supporting European
Marketing Authorization of Orphan Drugs: Comparison of Rare Oncology
versus Rare Disease
Author: Steven Kelly
Research Poster Presentations: Session I
PSY: Systemic Disorders/Conditions
Display Hours: 8:45 am to 1:45 pm CEST
-
Title: UK Health Technology Assessment of Orphan Drugs for Rare
Oncology versus Rare Disease: Does Orphan Designation Make any
Difference in HTA Process?
Author: Steven Kelly
Research Poster Presentations: Session I
PSY: Systemic Disorders/Conditions
Display Hours: 8:45 am to 1:45 pm CEST
-
Title: Is Adopting a Low Price Strategy to Gain Market Access
Compatible with a Viable Gene/Cell Therapy Business?
Author: Walter Colasante
Research Poster Presentations: Session I
PMU: Multiple Diseases
Display Hours: 8:45 am to 1:45 pm CEST
Tuesday, November 13, 2018
-
Title: Are Traditional Managed Entry Agreements Suitable for
Potentially, Curative Gene/Cell Therapies?
Author: Walter Colasante
Research Poster Presentations: Session III
PHP: Health Care Use & Policy Studies
Display Hours: 8:45 am to 1:30 pm CEST
-
Title: G-BA Conditional Approvals in the AMNOG Procedure: Impact on
HTA Outcomes and Price
Authors: Justus Dehnen with Dennis Petry, Fabian Kruse, and Jakob Bercher
Research Poster Presentations: Session III
PHP: Health Care Use & Policy Studies
Display Hours: 8:45 am to 1:30 pm CEST
-
Title: Impact of the Clinical Trial Design Strategy on Product Market
Uptake and Overall Commercial Success
Authors: Leanne Finch with Carla Fisher, Zlatina Dobreva, Jingyi Huang, and Hannah Armstrong
Research Poster Presentations: Session IV
PRM: Research on Methods
Display Hours: 3:30 pm to 7:00 pm CEST
About CRA's Life
Sciences Practice
The CRA Life Sciences Practice works with
leading biotech, medical device, and pharmaceutical companies; law
firms; regulatory agencies; and national and international industry
associations. We provide the analytical expertise and industry
experience needed to address our clients’ toughest issues. We have a
reputation for rigorous and innovative analysis, careful attention to
detail, and the ability to work effectively as part of a wider team of
advisers.
About Charles River Associates (CRA)
Charles River
Associates® is a global consulting firm specializing in economic,
financial, and management consulting services. CRA advises clients
on economic and financial matters pertaining to litigation and
regulatory proceedings, and guides corporations through critical
business strategy and performance-related issues. Since 1965, clients
have engaged CRA for its unique combination of functional expertise and
industry knowledge, and for its objective solutions to complex problems.
Headquartered in Boston, CRA has offices throughout the world. Detailed
information about Charles River Associates, a registered trade name
of CRA International, Inc., is available at www.crai.com.
Follow us on LinkedIn, Twitter,
and Facebook.